Arcutis Director Disposes $250K in Stock as Company Advances ZORYVE Program
Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares on February 2, 2026, in transactions that generated roughly $250,483. The sales were executed through a 10b5-1 trading plan established in March 2025. The company meanwhile reported positive Phase 2 data for ZORYVE in infants, transitioned promotion responsibilities in-house, appo…